Icecure Medical (XTAE:ICCM) Land And Improvements : ₪0.00 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Icecure Medical Land And Improvements?

Icecure Medical's land and improvements for the quarter that ended in Mar. 2024 was ₪0.00 Mil.

Icecure Medical Land And Improvements Historical Data

The historical data trend for Icecure Medical's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icecure Medical Land And Improvements Chart

Icecure Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Land And Improvements

Get a 7-Day Free Trial

Icecure Medical Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Icecure Medical Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Icecure Medical (XTAE:ICCM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Icecure Medical Ltd (XTAE:ICCM) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

ICCM:USA

Address

7 Haeshel Street, Southern Industrial Park, PO Box 3163, Caesarea, ISR, 3079504

Website

https://www.icecure-medical.com

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.